Paul Gunderson, MD | |
27129 Se 456th St, Enumclaw, WA 98022-9335 | |
(253) 332-6275 | |
Not Available |
Full Name | Paul Gunderson |
---|---|
Gender | Male |
Speciality | Surgery |
Location | 27129 Se 456th St, Enumclaw, Washington |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1669243036 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208600000X | Surgery | MD00016113 (Washington) | Primary |
Mailing Address | Practice Location Address |
---|---|
Paul Gunderson, MD 27129 Se 456th St, Enumclaw, WA 98022-9335 Ph: (253) 332-6275 | Paul Gunderson, MD 27129 Se 456th St, Enumclaw, WA 98022-9335 Ph: (253) 332-6275 |
News Archive
Jose Graziano da Silva, director-general of the U.N. Food and Agriculture Organization, writes in a Huffington Post opinion piece, My top priority for 2012 will be to make a renewed push towards achieving the first millennium development goal of halving the proportion of people living in hunger and extreme poverty by 2015, but also to look beyond it, to the final, total eradication of hunger from this planet.
PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it has secured exclusive rights to two issued U.S. patents from Hospital for Special Surgery, New York. PIKAMAB is developing Lupus TherasightTM, a novel theragnostic product that will eventually help guide the drug development process and patient treatment protocols in the areas of lupus and lupus nephritis.
The only drug currently approved for treatment of stroke's crippling effects shows promise, when administered as a nasal spray, to help heal similar damage in less severe forms of traumatic brain injury.
BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, announced that it has begun a new Phase IIa clinical testing of ProtoCure emulsion cream, the company's novel topical drug for dermatology.
The medical technology developed by Integrated Medical Systems, Inc., has been recognized by the U.S. Department of Health and Human Services and the U.S. Treasury Department as a "qualified therapeutic discovery." The designation earns the company a grant to off-set its development efforts. The Qualifying Therapeutic Discovery Project designation and grant is provided for under the Patient Protection and Affordable Care Act of 2010.
› Verified 5 days ago
Samuel E Cargill, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1818 Cole St, Enumclaw, WA 98022 Phone: 360-802-5760 Fax: 360-802-5799 |